Nature Communications (Oct 2016)
SIKs control osteocyte responses to parathyroid hormone
- Marc N. Wein,
- Yanke Liang,
- Olga Goransson,
- Thomas B. Sundberg,
- Jinhua Wang,
- Elizabeth A. Williams,
- Maureen J. O’Meara,
- Nicolas Govea,
- Belinda Beqo,
- Shigeki Nishimori,
- Kenichi Nagano,
- Daniel J. Brooks,
- Janaina S. Martins,
- Braden Corbin,
- Anthony Anselmo,
- Ruslan Sadreyev,
- Joy Y. Wu,
- Kei Sakamoto,
- Marc Foretz,
- Ramnik J. Xavier,
- Roland Baron,
- Mary L. Bouxsein,
- Thomas J. Gardella,
- Paola Divieti-Pajevic,
- Nathanael S. Gray,
- Henry M. Kronenberg
Affiliations
- Marc N. Wein
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Yanke Liang
- Department of Biologic Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Harvard Medical School
- Olga Goransson
- Department of Experimental Medical Sciences, Lund University
- Thomas B. Sundberg
- Center for the Development of Therapeutics, Broad Institute
- Jinhua Wang
- Department of Biologic Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Harvard Medical School
- Elizabeth A. Williams
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Maureen J. O’Meara
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Nicolas Govea
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Belinda Beqo
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Shigeki Nishimori
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Kenichi Nagano
- Department of Oral Medicine, Harvard School of Dental Medicine, Infection, and Immunity, 188 Longwood Avenue, Boston, Massachusetts 02115, US
- Daniel J. Brooks
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Janaina S. Martins
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Braden Corbin
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Anthony Anselmo
- Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School
- Ruslan Sadreyev
- Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School
- Joy Y. Wu
- Division of Endocrinology, Department of Medicine, Stanford University School of Medicine
- Kei Sakamoto
- MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee
- Marc Foretz
- INSERM U1016, Institut Cochin, CNRS UMR8104, Universite Paris Descartes Sorbonne Pairs Cite
- Ramnik J. Xavier
- Department of Medicine, Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital
- Roland Baron
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Mary L. Bouxsein
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Thomas J. Gardella
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- Paola Divieti-Pajevic
- Henry M. Goldman School of Dental Medicine, Boston University
- Nathanael S. Gray
- Department of Biologic Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Harvard Medical School
- Henry M. Kronenberg
- Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard Medical School
- DOI
- https://doi.org/10.1038/ncomms13176
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 19
Abstract
Parathyroid hormone (PTH) is an endogenous hormone and osteoporosis therapeutic that suppresses sclerostin activity. Here the authors develop SIK inhibitors as potential therapeutic tools and use them to show that PTH-cAMP signalling in osteocytes inhibits SIK2 from driving Hdac4/5 nuclear shuttling to suppress sclerostin.
